- CA$8.66m
- CA$4.70m
- CA$21.69m
- 28
- 79
- 49
- 51
Annual income statement for Medicure, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 20.2 | 11.6 | 21.7 | 23.1 | 21.7 |
Cost of Revenue | |||||
Gross Profit | 12.9 | 5.13 | 12.7 | 16.1 | 14 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 34.7 | 19.7 | 23.8 | 21.9 | 22.5 |
Operating Profit | -14.6 | -8.11 | -2.09 | 1.19 | -0.854 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -19.6 | -6.84 | -0.759 | 1.39 | -0.897 |
Provision for Income Taxes | |||||
Net Income After Taxes | -19.8 | -6.84 | -0.727 | 1.36 | -0.922 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -19.8 | -6.84 | -0.727 | 1.36 | -0.922 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -19.8 | -6.84 | -0.727 | 1.36 | -0.922 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.04 | -0.721 | -0.104 | 0.131 | -0.088 |